*Correspondence: Peng Xu, [email protected] ORCID: Lin Liu, Jiachen Wang, Weikun Hou, This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
This might initially seem counterintuitive, but controlled matrix degradation is essential for tissue remodeling and replacement of damaged structural proteins with newly synthesized, functional equivalents
Your recovery should work the same way
Set out plainly: Limitations of the evidence base No human dose-ranging study exists
Using U-40 calculations on a U-100 syringe causes a 2.5x dosing error
While promising, evidence is limited to preclinical data with no registered clinical trials to date, and thus human efficacy and safety remain to be established
